Anika Therapeutics (ANIK) Tops Q2 EPS by 32c

Anika Therapeutics (NASDAQ: ANIK) reported Q2 EPS of $0.76, $0.32 better than the analyst estimate of $0.44. Revenue for the quarter came in at $33.46 million versus the consensus estimate of $27.2 million.

For earnings history and earnings-related data on Anika Therapeutics (ANIK) click here.

You May Also Be Interested In

• BJ's Wholesale Club (BJ) Tops Q2 EPS by 19c, Beats on Revenue; Offers FY27 EPS Guidance
• Ubiquiti (UI) Tops Q4 EPS by 25c, Beats on Revenue
• BofA maintains underperform ratings on six BDC stocks